X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
Retrieved on:
Tuesday, October 19, 2021
Takeda Pharmaceutical Company, Security (finance), Medication, Lists of people executed in the United States, GLOBE, Patient, University, Associate Director of National Intelligence and Chief Information Officer, Novartis, Safety, Vertex Pharmaceuticals, Clinical trial, Immune system, University of Leuven, Risk, WHIM, Private Securities Litigation Reform Act, COVID-19, SCN, Yale University, U.S. Commercial Service in Taiwan, Board, Immunodeficiency, Biogen, Faculty, SEC, Hotel manager, General manager, Biology, Marketing, Joseph De Craecker, U.S. Securities and Exchange Commission, Growth, Senior, CXCR4, EMEA, Forward-looking statement, Cancer, Lead, WHIM syndrome, HCP, Nutrition, Research, University of Freiburg Faculty of Medicine, Therapy, Pharmaceutical industry, Management
Ms. de Craeckers appointment expands the X4 Board of Directors to nine members.
Key Points:
- Ms. de Craeckers appointment expands the X4 Board of Directors to nine members.
- Ms. de Craecker joins the X4 Board of Directors following a distinguished career building multi-functional teams, formulating global commercial strategies for orphan drug and gene therapy products, and successfully launching multiple products across the globe.
- Prior to that, Ms. de Craecker served as Senior Vice President and General Manager EMEA at Raptor Pharmaceuticals Europe.
- Ms. Park joined X4 in September 2021 as Vice President, U.S. Commercial, bringing nearly 20 years of experience in life science marketing and commercial planning, development, and execution.